CONMED Corporation, a medical technology company, develops, manufactures, and sells surgical devices and related equipment for minimally invasive procedures worldwide. It offers orthopedic surgery products, including sports medicine products comprising powered resection instruments, arthroscopes, reconstructive systems, tissue repair sets, and metal and bioabsorbable implants, as well as related disposable products and fluid management systems; powered surgical instruments for use in bone orthopedic, arthroscopic, oral/maxillofacial, podiatric, spinal, and cardiothoracic surgeries; sports biologics and tissue products; and surgical visualization products. The company markets orthopedic surgery products under the Hall, CONMED Linvatec, Concept, and Shutt brands. It also offers general surgery products, such as clinical insufflation, smoke evacuation, electrosurgical, and endomechanical products; and endoscopic technologies, including diagnostic and therapeutic products for use in gastroenterology procedures, and products for the treatment of diseases of the biliary structures, as well as cardiac monitoring products comprising ECG and EEG electrodes, and cardiac defibrillation pads. The company markets its products directly to hospitals, surgery centers, and other healthcare institutions, as well as through medical specialty distributors. CONMED Corporation was incorporated in 1970 and is headquartered in Largo, Florida.
IPO Year: 1987
Exchange: NYSE
Website: conmed.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 6/12/2025 | Buy → Hold | Needham | |
| 4/28/2025 | $55.00 | Buy → Hold | Stifel |
| 2/6/2025 | $85.00 → $70.00 | Overweight → Neutral | Analyst |
| 2/1/2024 | $119.00 → $129.00 | Buy | Needham |
| 5/22/2023 | $140.00 | Buy | CL King |
| 3/27/2023 | $124.00 | Sector Weight → Overweight | KeyBanc Capital Markets |
| 3/21/2023 | $96.00 | Equal Weight | Wells Fargo |
| 10/12/2022 | $85.00 | Hold | Jefferies |
| 3/2/2022 | $155.00 | Neutral | BofA Securities |
| 1/21/2022 | $158.00 → $150.00 | Buy | Needham |
4 - CONMED Corp (0000816956) (Issuer)
4 - CONMED Corp (0000816956) (Issuer)
4 - CONMED Corp (0000816956) (Issuer)
4 - CONMED Corp (0000816956) (Issuer)
4 - CONMED Corp (0000816956) (Issuer)
4 - CONMED Corp (0000816956) (Issuer)
4 - CONMED Corp (0000816956) (Issuer)
4 - CONMED Corp (0000816956) (Issuer)
4 - CONMED Corp (0000816956) (Issuer)
4 - CONMED Corp (0000816956) (Issuer)
4 - CONMED Corp (0000816956) (Issuer)
4 - CONMED Corp (0000816956) (Issuer)
4 - CONMED Corp (0000816956) (Issuer)
4 - CONMED Corp (0000816956) (Issuer)
11-K - CONMED Corp (0000816956) (Filer)
8-K - CONMED Corp (0000816956) (Filer)
SD - CONMED Corp (0000816956) (Filer)
8-K - CONMED Corp (0000816956) (Filer)
S-8 POS - CONMED Corp (0000816956) (Filer)
S-8 POS - CONMED Corp (0000816956) (Filer)
S-8 - CONMED Corp (0000816956) (Filer)
DEFA14A - CONMED Corp (0000816956) (Filer)
10-Q - CONMED Corp (0000816956) (Filer)
8-K - CONMED Corp (0000816956) (Filer)
CONMED Corporation (NYSE:CNMD) today announced that it will report financial results for the second quarter 2025 after the market close on Wednesday, July 30, 2025. The Company's management will host a conference call at 4:30 p.m. ET that same day to discuss the results. To participate in the conference call via telephone, please click here to pre-register and obtain the dial-in number and passcode. This conference call will also be webcast and can be accessed from the "Investors" section of CONMED's website at www.conmed.com. The webcast replay of the call will be available at the same site approximately one hour after the end of the call. About CONMED Corporation CONMED is a medic
CONMED Corporation (NYSE:CNMD) today announced that LaVerne Council has been appointed to succeed Martha Goldberg Aronson as the new Independent Chair of its Board of Directors, effective May 21, 2025. "LaVerne's extensive experience as a global operations and information technology executive have been invaluable to CONMED, and I know that her experience will continue to serve the Board and the Company well in her new role as Chair of the Board," said Pat Beyer, President and Chief Executive Officer, CONMED. "I also want to thank Martha for her ongoing contributions to CONMED. Martha's strategic direction and steady leadership have been crucial to CONMED in her role as Chair, and her conti
CONMED Corporation (NYSE:CNMD) today announced that its Board of Directors declared a quarterly cash dividend of $0.20 per share on May 20, 2025, payable on July 3, 2025, to all shareholders of record as of June 13, 2025. About CONMED Corporation CONMED is a medical technology company that provides devices and equipment for surgical procedures. The Company's products are used by surgeons and other healthcare professionals in a variety of specialties, including orthopedics, general surgery, gynecology, thoracic surgery, and gastroenterology. For more information, visit www.conmed.com. Forward-Looking Statements This press release may contain forward-looking statements based on certain as
CONMED Corporation (NYSE:CNMD) today announced financial results for the first quarter ended March 31, 2025. First Quarter 2025 Highlights Sales of $321.3 million increased 2.9% year-over-year as reported and 3.8% in constant currency. Domestic revenue increased 4.2% year-over-year. International revenue increased 1.2% year-over-year as reported and 3.4% in constant currency. Diluted net earnings per share (GAAP) were $0.19, compared to diluted net earnings per share (GAAP) of $0.63 in the first quarter of 2024. Adjusted diluted net earnings per share(1) were $0.95, compared to adjusted diluted net earnings per share of $0.79 in the first quarter of 2024. "We had a good start t
CONMED Corporation (NYSE:CNMD) today announced that it will report financial results for the first quarter 2025 after the market close on Wednesday, April 30, 2025. The Company's management will host a conference call at 4:30 p.m. ET that same day to discuss the results. To participate in the conference call via telephone, please click here to pre-register and obtain the dial-in number and passcode. This conference call will also be webcast and can be accessed from the "Investors" section of CONMED's website at www.conmed.com. The webcast replay of the call will be available at the same site approximately one hour after the end of the call. About CONMED Corporation CONMED is a medical t
CONMED Corporation (NYSE:CNMD) today announced that Mark Kaye will be joining its Board of Directors effective February 24th, 2025. "My fellow directors and I are extremely pleased to welcome Mark to the board," said Martha Goldberg Aronson, Chair of CONMED's Board of Directors. "Mark brings a wealth of experience to CONMED, including deep knowledge across finance, accounting, risk management, strategic planning, and operational efficiencies. He also brings a strong background and expertise in both corporate governance and healthcare. Mark's skills and insights will help guide CONMED's future direction." "Mark is an outstanding addition to our board," said Patrick Beyer, President and C
CONMED Corporation (NYSE:CNMD) announced today that its Board of Directors declared a quarterly cash dividend of $0.20 per share on February 24, 2025, payable on April 4, 2025, to all shareholders of record as of March 14, 2025. About CONMED Corporation CONMED is a medical technology company that provides devices and equipment for surgical procedures. The Company's products are used by surgeons and other healthcare professionals in a variety of specialties, including orthopedics, general surgery, gynecology, thoracic surgery, and gastroenterology. For more information, visit www.conmed.com. Forward-Looking Statements This press release may contain forward-looking statements based on
CONMED Corporation (NYSE:CNMD) today announced financial results for the fourth quarter and full-year ended December 31, 2024. Fourth Quarter 2024 Highlights Sales of $345.9 million increased 5.8% year over year as reported and 6.0% in constant currency. Domestic revenue increased 6.8% year over year. International revenue increased 4.4% year over year as reported and 5.0% in constant currency. Diluted net earnings per share (GAAP) were $1.08 compared to diluted net earnings per share (GAAP) of $1.05 in the fourth quarter of 2023. Adjusted diluted net earnings per share(1) were $1.34, an increase of 26.4% compared to the fourth quarter of 2023. Full-Year 2024 Highlights
CONMED Corporation (NYSE:CNMD) today announced that it will report financial results for the fourth quarter 2024 after the market close on Wednesday, February 5, 2025. The Company's management will host a conference call at 4:30 p.m. ET that same day to discuss the results. To participate in the conference call via telephone, please click here to pre-register and obtain the dial-in number and passcode. This conference call will also be webcast and can be accessed from the "Investors" section of CONMED's website at www.conmed.com. The webcast replay of the call will be available at the same site approximately one hour after the end of the call. About CONMED Corporation CONMED is a me
CONMED Corporation (NYSE:CNMD) today announced that Patrick J. Beyer, President and Chief Executive Officer, and Todd W. Garner, Executive Vice President and Chief Financial Officer, will present at the J.P. Morgan Healthcare Conference at 4:30 p.m. PT (7:30 p.m. ET) on Monday, January 13, 2025 in San Francisco, CA. A live audio webcast of the presentation will be accessible through the "Investors" section of the Company's website at www.conmed.com and will be available for replay following the event. About CONMED Corporation CONMED is a medical technology company that provides devices and equipment for surgical procedures. The Company's products are used by surgeons and other hea
Needham downgraded CONMED from Buy to Hold
Stifel downgraded CONMED from Buy to Hold and set a new price target of $55.00
Analyst downgraded CONMED from Overweight to Neutral and set a new price target of $70.00 from $85.00 previously
Needham reiterated coverage of CONMED with a rating of Buy and set a new price target of $129.00 from $119.00 previously
CL King initiated coverage of CONMED with a rating of Buy and set a new price target of $140.00
KeyBanc Capital Markets upgraded CONMED from Sector Weight to Overweight and set a new price target of $124.00
Wells Fargo initiated coverage of CONMED with a rating of Equal Weight and set a new price target of $96.00
Jefferies initiated coverage of CONMED with a rating of Hold and set a new price target of $85.00
BofA Securities resumed coverage of CONMED with a rating of Neutral and set a new price target of $155.00
Needham reiterated coverage of Conmed with a rating of Buy and set a new price target of $150.00 from $158.00 previously
CONMED Corporation (NYSE:CNMD) today announced that LaVerne Council has been appointed to succeed Martha Goldberg Aronson as the new Independent Chair of its Board of Directors, effective May 21, 2025. "LaVerne's extensive experience as a global operations and information technology executive have been invaluable to CONMED, and I know that her experience will continue to serve the Board and the Company well in her new role as Chair of the Board," said Pat Beyer, President and Chief Executive Officer, CONMED. "I also want to thank Martha for her ongoing contributions to CONMED. Martha's strategic direction and steady leadership have been crucial to CONMED in her role as Chair, and her conti
CONCORD, Mass.--(BUSINESS WIRE)--Beta Bionics, Inc., a medical technology company focused on the design, development, and commercialization of the iLet® bionic pancreas system, today announced the appointment of Martha Goldberg Aronson as Chair of its Board of Directors, effective immediately. Ms. Aronson, who joined the Beta Bionics Board as a Director in February of 2020, succeeds Ed Damiano, President and Chief Executive Officer of Beta Bionics, who has served as Chair since inception of the company in 2015. Dr. Damiano will remain a member of the Board while continuing to serve in his roles as President and Chief Executive Officer of Beta Bionics. “On behalf of the Board, I am
SC 13G/A - CONMED Corp (0000816956) (Subject)
SC 13G/A - CONMED Corp (0000816956) (Subject)
SC 13G/A - CONMED Corp (0000816956) (Subject)
SC 13G/A - CONMED Corp (0000816956) (Subject)
SC 13G/A - CONMED Corp (0000816956) (Subject)
SC 13G - CONMED Corp (0000816956) (Subject)
SC 13G/A - CONMED Corp (0000816956) (Subject)
SC 13G/A - CONMED Corp (0000816956) (Subject)
SC 13G/A - CONMED Corp (0000816956) (Subject)
SC 13G/A - CONMED Corp (0000816956) (Subject)
CONMED Corporation (NYSE:CNMD) today announced that it will report financial results for the second quarter 2025 after the market close on Wednesday, July 30, 2025. The Company's management will host a conference call at 4:30 p.m. ET that same day to discuss the results. To participate in the conference call via telephone, please click here to pre-register and obtain the dial-in number and passcode. This conference call will also be webcast and can be accessed from the "Investors" section of CONMED's website at www.conmed.com. The webcast replay of the call will be available at the same site approximately one hour after the end of the call. About CONMED Corporation CONMED is a medic
CONMED Corporation (NYSE:CNMD) today announced that its Board of Directors declared a quarterly cash dividend of $0.20 per share on May 20, 2025, payable on July 3, 2025, to all shareholders of record as of June 13, 2025. About CONMED Corporation CONMED is a medical technology company that provides devices and equipment for surgical procedures. The Company's products are used by surgeons and other healthcare professionals in a variety of specialties, including orthopedics, general surgery, gynecology, thoracic surgery, and gastroenterology. For more information, visit www.conmed.com. Forward-Looking Statements This press release may contain forward-looking statements based on certain as
CONMED Corporation (NYSE:CNMD) today announced financial results for the first quarter ended March 31, 2025. First Quarter 2025 Highlights Sales of $321.3 million increased 2.9% year-over-year as reported and 3.8% in constant currency. Domestic revenue increased 4.2% year-over-year. International revenue increased 1.2% year-over-year as reported and 3.4% in constant currency. Diluted net earnings per share (GAAP) were $0.19, compared to diluted net earnings per share (GAAP) of $0.63 in the first quarter of 2024. Adjusted diluted net earnings per share(1) were $0.95, compared to adjusted diluted net earnings per share of $0.79 in the first quarter of 2024. "We had a good start t
CONMED Corporation (NYSE:CNMD) today announced that it will report financial results for the first quarter 2025 after the market close on Wednesday, April 30, 2025. The Company's management will host a conference call at 4:30 p.m. ET that same day to discuss the results. To participate in the conference call via telephone, please click here to pre-register and obtain the dial-in number and passcode. This conference call will also be webcast and can be accessed from the "Investors" section of CONMED's website at www.conmed.com. The webcast replay of the call will be available at the same site approximately one hour after the end of the call. About CONMED Corporation CONMED is a medical t
CONMED Corporation (NYSE:CNMD) announced today that its Board of Directors declared a quarterly cash dividend of $0.20 per share on February 24, 2025, payable on April 4, 2025, to all shareholders of record as of March 14, 2025. About CONMED Corporation CONMED is a medical technology company that provides devices and equipment for surgical procedures. The Company's products are used by surgeons and other healthcare professionals in a variety of specialties, including orthopedics, general surgery, gynecology, thoracic surgery, and gastroenterology. For more information, visit www.conmed.com. Forward-Looking Statements This press release may contain forward-looking statements based on
CONMED Corporation (NYSE:CNMD) today announced financial results for the fourth quarter and full-year ended December 31, 2024. Fourth Quarter 2024 Highlights Sales of $345.9 million increased 5.8% year over year as reported and 6.0% in constant currency. Domestic revenue increased 6.8% year over year. International revenue increased 4.4% year over year as reported and 5.0% in constant currency. Diluted net earnings per share (GAAP) were $1.08 compared to diluted net earnings per share (GAAP) of $1.05 in the fourth quarter of 2023. Adjusted diluted net earnings per share(1) were $1.34, an increase of 26.4% compared to the fourth quarter of 2023. Full-Year 2024 Highlights
CONMED Corporation (NYSE:CNMD) today announced that it will report financial results for the fourth quarter 2024 after the market close on Wednesday, February 5, 2025. The Company's management will host a conference call at 4:30 p.m. ET that same day to discuss the results. To participate in the conference call via telephone, please click here to pre-register and obtain the dial-in number and passcode. This conference call will also be webcast and can be accessed from the "Investors" section of CONMED's website at www.conmed.com. The webcast replay of the call will be available at the same site approximately one hour after the end of the call. About CONMED Corporation CONMED is a me
CONMED Corporation (NYSE:CNMD) announced today that its Board of Directors declared a quarterly cash dividend of $0.20 per share on December 9, 2024, payable on January 3, 2025, to all shareholders of record as of December 20, 2024. About CONMED Corporation CONMED is a medical technology company that provides devices and equipment for surgical procedures. The Company's products are used by surgeons and other healthcare professionals in a variety of specialties, including orthopedics, general surgery, gynecology, thoracic surgery, and gastroenterology. For more information, visit www.conmed.com. Forward-Looking Statements This press release may contain forward-looking statements base
CONMED Corporation (NYSE:CNMD) today announced financial results for the third quarter ended September 30, 2024. Third Quarter 2024 Highlights Sales of $316.7 million increased 4.0% year-over-year as reported and 4.3% in constant currency. Diluted net earnings per share (GAAP) were $1.57 compared to diluted net earnings per share (GAAP) of $0.50 in the third quarter of 2023. Adjusted diluted net earnings per share(1) were $1.05, an increase of 16.7% compared to the third quarter of 2023. Announced COO Patrick Beyer to succeed Curt Hartman as President and CEO effective January 1, 2025, upon Mr. Hartman's retirement. "Our third quarter results were largely in line with our expecta
As a follow up to the Current Report on Form 8-K issued by the Company on September 30, 2024, CONMED Corporation (NYSE:CNMD) announced preliminary financial information for the third quarter of 2024. The Company expects revenue in the range of $315 million to $318 million and adjusted diluted net earnings per share growth in excess of its previously provided guidance of 9% to 11%. CONMED will report full financial results for the third quarter of 2024 after the market close on Wednesday, October 30, 2024. The Company's management will host a conference call at 4:30 p.m. ET that same day to discuss the results. To participate in the conference call via telephone, please click here to pre-r